The complexity of achieving anticoagulation control in the face of warfarin – phenytoin interaction: an Asian case report
Phenytoin has been reported to have major interactions with warfarin. Phenytoin induces warfarin’s metabolism. However, there are many case reports which provide conflicting conclusions. Here, we report a case of a 65-year-old man with mechanical heart valve on chronic warfarin therapy who experienced persistent fluctuations of INR and bleeding secondary to probable warfarin–phenytoin interactions. The patient’s anticoagulation clinic visits prior to hospitalization were thoroughly evaluated and we continued to follow-up the case for 3 months post-hospitalization. The reported interaction could be reasonably explained from the chronology of events and the pattern of INR fluctuations whenever phenytoin was either added or discontinued from his drug regimen.
KeywordsAnticoagulation Bleeding INR Phenytoin Warfarin interactions
Cropp, JS, Bussey, HI 1997A review of enzyme induction of warfarin metabolism with recommendations for patient management.Pharmacotherapy1791728PubMedGoogle Scholar Wells, PS, Holbrook, AM, Crowther, NR, et al. 1994The interaction of warfarin with drugs and food: a critical review of the literature.Ann Intern Med12167683PubMedGoogle Scholar MacKichan, JJ 1984Pharmacokinetic consequences of drug displacement from blood and tissue proteins.Clin Pharmacokinet93241PubMedGoogle Scholar Myers, SP 2002Interactions between complementary medicines and warfarin.Aust Prescr25546Google Scholar Cannegieter, SC, Rosendaal, FR, Wintzen, AR, et al. 1995Optimal oral anticoagulation therapy in patients with mechanical heart valves.N Engl J Med333117CrossRefPubMedGoogle Scholar Donnell, MO, Hirsh, J 2004Establishing an optimal therapeutic range for coumarins: filling in the gaps.Arch Intern Med16458890CrossRefPubMedGoogle Scholar Hirsh, J, Dalen, JE, Anderson, DR, et al. 2001Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.Chest1198S21SCrossRefPubMedGoogle Scholar White, RH, Mckittrick, T, Hutchinson, R, et al. 1995Temporary discontinuation of warfarin therapy: changes in the INR.Ann Intern Med122402PubMedGoogle Scholar Ansell, J, Hirsh, J, Dalen, J, et al. 2001Managing oral anticoagulant therapy.Chest11922S38SCrossRefPubMedGoogle Scholar Furuya, H, Fernadez-Salguero, P, Gregory, W, et al. 1995Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirements in patients undergoing anticoagulation therapy.Pharmacogenetics538992PubMedGoogle Scholar Kamali, F, Khan, TI, King, BP, et al. 2004Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.Clin Phamacol Ther7520412CrossRefGoogle Scholar Loebstein, R, Yonath, H, Peleg, D, et al. 2001Interindividual variability in sensitivity to warfarin–nature or nurture?Clin Pharmacol Ther7015964CrossRefPubMedGoogle Scholar Peyvandi, F, Spreafico, M, Siboni, SM, Moia, M, Mannucci, PM 2004CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.Clin Phamacol Ther75198203CrossRefGoogle Scholar Naranjo, CA, Busto, U, Sellers, EM, et al. 1981A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther3023945PubMedGoogle Scholar To, E, Jackevicius, C 2002Quality improvement initiative for pharmacist-assisted warfarin dosing: implementation and evaluation of a new protocol.Can J Hosp Pharm5510513Google Scholar